Fusion Proteins: Aflibercept (VEGF Trap-Eye)

Basit Öğe Kaydı
dc.contributor.authorSarwar, Salman
dc.contributor.authorBakbak, Berker
dc.contributor.authorSadiq, Mohammad Ali
dc.contributor.authorSepah, Yasir J.
dc.contributor.authorShah, Syed Mahmood
dc.contributor.authorIbrahim, Mohamed
dc.contributor.authorDo, Diana V.
dc.date.accessioned2020-03-26T19:24:20Z
dc.date.available2020-03-26T19:24:20Z
dc.date.issued2016
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractVascular endothelial growth factor (VEGF) inhibitors currently used to treat eye diseases have included monoclonal antibodies, antibody fragments, and an aptamer. A different method of achieving VEGF blockade in retinal diseases includes the concept of a cytokine trap. Cytokine traps are being evaluated for the treatment of various diseases that are driven by excessive cytokine levels. Traps, such as VEGF Trap, consist of two extracellular cytokine receptor domains fused together to form a human IgG. Aflibercept (VEGF Trap-Eye) is a soluble fusion protein which combines ligand-binding elements taken from the extracellular components of VEGF receptor (VEGFR)-1 and VEGFR-2 fused to the Fc portion of IgG. This protein contains all human amino-acid sequences, which minimizes the potential for immunogenicity in human patients. The chapter will summarize the chemical properties of aflibercept and the various studies that have demonstrated a role of aflibercept in the management of retinal vascular diseases such as neovascular age-related macular degeneration, diabetic retinopathy, macular edema, and retinal vein occlusion. (C) 2016 S. Karger AG, Baselen_US
dc.identifier.doi10.1159/000439008en_US
dc.identifier.endpage294en_US
dc.identifier.isbn978-3-318-05565-8; 978-3-318-05564-1
dc.identifier.issn0250-3751en_US
dc.identifier.pmid26501481en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage282en_US
dc.identifier.urihttps://dx.doi.org/10.1159/000439008
dc.identifier.urihttps://hdl.handle.net/20.500.12395/33633
dc.identifier.volume55en_US
dc.identifier.wosWOS:000413475300032en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKARGERen_US
dc.relation.ispartofRETINAL PHARMACOTHERAPEUTICSen_US
dc.relation.ispartofseriesDevelopments in Ophthalmology
dc.relation.publicationcategoryKitap Bölümü - Uluslararasıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.titleFusion Proteins: Aflibercept (VEGF Trap-Eye)en_US
dc.typeBook Chapteren_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu